Close Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Close Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$40K	Hold	11,675	–	–	﹤0.01%	185
2025 Q4	$33K	Hold	11,675	–	–	﹤0.01%	193
2025 Q3	$31K	Hold	11,675	–	–	﹤0.01%	193
2025 Q2	$26K	Hold	11,675	–	–	﹤0.01%	192
2025 Q1	$25K	Buy	11,675 +275	+2%	+$635	﹤0.01%	183
2024 Q4	$28K	Hold	11,400	–	–	﹤0.01%	177
2024 Q3	$28K	Hold	11,400	–	–	﹤0.01%	186
2024 Q2	$29K	Hold	11,400	–	–	﹤0.01%	185
2024 Q1	$33K	Hold	11,400	–	–	﹤0.01%	174
2023 Q4	$26K	Hold	11,400	–	–	﹤0.01%	172
2023 Q3	$30K	Hold	11,400	–	–	﹤0.01%	160
2023 Q2	$41K	Buy	11,400 +2,500	+28%	+$8.02K	﹤0.01%	164
2023 Q1	$19K	Buy	8,900 +5,700	+178%	+$18.1K	﹤0.01%	182
2022 Q4	$39K	Hold	3,200	–	–	﹤0.01%	134
2022 Q3	$21K	Buy	3,200 +1,100	+52%	+$8.9K	﹤0.01%	139
2022 Q2	$10K	Hold	2,100	–	–	﹤0.01%	162
2022 Q1	$30K	Hold	2,100	–	–	﹤0.01%	145
2021 Q4	$30K	Sell	2,100 -1,070	-34%	-$22.4K	﹤0.01%	145
2021 Q3	$70K	Buy	3,170 +670	+27%	+$11.4K	﹤0.01%	107
2021 Q2	$33K	Sell	2,500 -5,000	-67%	-$57.2K	﹤0.01%	142
2021 Q1	$76K	Hold	7,500	–	–	﹤0.01%	123
2020 Q4	$32K	Hold	7,500	–	–	﹤0.01%	100
2020 Q3	$20K	Hold	7,500	–	–	﹤0.01%	110
2020 Q2	$26K	Hold	7,500	–	–	﹤0.01%	114
2020 Q1	$23K	Hold	7,500	–	–	﹤0.01%	118
2019 Q4	$39K	Hold	7,500	–	–	﹤0.01%	122
2019 Q3	$24K	Hold	7,500	–	–	﹤0.01%	132
2019 Q2	$27K	Hold	7,500	–	–	﹤0.01%	132
2019 Q1	$27K	Buy	7,500 +7,300	+3,650%	+$24.1K	﹤0.01%	144
2018 Q4	$51K	Sell	200 -1,800	-90%	-$7.45K	0.01%	119
2018 Q3	$10K	Buy	2,000 +1,250	+167%	+$6.49K	﹤0.01%	186
2018 Q2	$5K	Hold	750	–	–	﹤0.01%	197
2018 Q1	$5K	Hold	750	–	–	﹤0.01%	207
2017 Q4	$7K	Hold	750	–	–	﹤0.01%	198
2017 Q3	$7K	Hold	750	–	–	﹤0.01%	187
2017 Q2	$6K	Hold	750	–	–	﹤0.01%	194
2017 Q1	$5K	Hold	750	–	–	﹤0.01%	198
2016 Q4	$5K	Buy	+750	New	+$4.88K	﹤0.01%	132

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Close Asset Management's ORMP Position: Q1 2026 in Review

Close Asset Management held its Oramed Pharmaceuticals (ORMP) position steady in Q1 2026 at 11,675 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #185.

Close Asset Management first reported a position in ORMP in Q4 2016 and has held it in 38 quarters since. The position peaked at $76K in Q1 2021. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

Close Asset Management held 11,675 shares of Oramed Pharmaceuticals worth $40K as of Q1 2026.
Close Asset Management left its Oramed Pharmaceuticals share count unchanged in Q1 2026.
Oramed Pharmaceuticals made up ﹤0.01% of Close Asset Management's portfolio in Q1 2026, its #185 holding.
Close Asset Management first reported a position in Oramed Pharmaceuticals in Q4 2016 and has held it in 38 quarters since.
Close Asset Management's Oramed Pharmaceuticals position peaked at $76K in Q1 2021.
64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Close Asset Management's 13F filing for Q1 2026, filed 12 May 2026.